High efficacy therapy to prevent the formation of meningeal tertiary lymphoid organs after CXCL13 index screening in early multiple sclerosis DOI Creative Commons
Ana C. Londoño, Carlos A. Mora

Frontiers in Neuroscience, Journal Year: 2025, Volume and Issue: 19

Published: March 17, 2025

Postmortem studies have shown the presence of subpial inflammation with tertiary lymphoid organs (TLO) in meninges patients progressive multiple sclerosis, playing an important role pathophysiology disease. The chemokine (C-X-C motif) ligand 13 (CXCL13) induces formation these organs, thus promoting activity progression to disability sclerosis has been reduced, thanks effect disease modifying therapy. However, despite advances treatment immunomodulatory agents, we still lack specific laboratory biomarkers that could indicate state disease, either at time diagnosis or when escalation therapy seems be mandatory. In MRI not demonstrated TLO CNS, so far. determination CXCL13 index (ICXCL 13), clinical specimens, become a reliable biomarker for verification and TLO, contributing improving outcome, high efficacy therapy, setting.

Language: Английский

High efficacy therapy to prevent the formation of meningeal tertiary lymphoid organs after CXCL13 index screening in early multiple sclerosis DOI Creative Commons
Ana C. Londoño, Carlos A. Mora

Frontiers in Neuroscience, Journal Year: 2025, Volume and Issue: 19

Published: March 17, 2025

Postmortem studies have shown the presence of subpial inflammation with tertiary lymphoid organs (TLO) in meninges patients progressive multiple sclerosis, playing an important role pathophysiology disease. The chemokine (C-X-C motif) ligand 13 (CXCL13) induces formation these organs, thus promoting activity progression to disability sclerosis has been reduced, thanks effect disease modifying therapy. However, despite advances treatment immunomodulatory agents, we still lack specific laboratory biomarkers that could indicate state disease, either at time diagnosis or when escalation therapy seems be mandatory. In MRI not demonstrated TLO CNS, so far. determination CXCL13 index (ICXCL 13), clinical specimens, become a reliable biomarker for verification and TLO, contributing improving outcome, high efficacy therapy, setting.

Language: Английский

Citations

0